If you have been reading about Synaptogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
| Property | Value | Notes |
|---|---|---|
| Chemical name | N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Common full name in research literature. |
| Class | Synthetic peptide | Modified angiotensin IV analog. |
| Related compound | Angiotensin IV | Parent peptide fragment. |
| Proposed target | HGF/c-Met pathway | Described as an HGF mimetic; not fully confirmed. |
| Development status | Preclinical research | No widely approved clinical use. |
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
As a result of the mid-17th century Khmelnytsky Uprising, the Zaporozhian Cossacks briefly established an independent state, which later became the autonomous Cossack Hetmanate (1649–1764). It was placed under the suzerainty of the Russian Tsar from 1667 but was ruled by local hetmans for a century. The principal political problem of the hetmans who followed the Pereyeslav Agreement was defending the autonomy of the Hetmanate from Russian/Muscovite centralism. The hetmans Ivan Vyhovsky, Petro Doroshenko and Ivan Mazepa attempted to resolve this by separating Ukraine from Russia. Relations between the Hetmanate and their new sovereign began to deteriorate after the autumn of 1656, when the Muscovites, going against the wishes of their Cossack partners, signed an armistice with the Polish-Lithuanian Commonwealth in Vilnius. The Cossacks considered the Vilnius agreement a breach of the contract they had entered into at Pereiaslav. For the Muscovite tsar, the Pereiaslav Agreement signified the unconditional submission of his new subjects; the Ukrainian hetman considered it a conditional contract from which one party could withdraw if the other was not upholding its end of the bargain. The Ukrainian hetman Ivan Vyhovsky, who succeeded Khmelnytsky in 1657, believed the Tsar was not living up to his responsibility. Accordingly, he concluded a treaty with representatives of the Polish king, who agreed to re-admit Cossack Ukraine by reforming the Polish-Lithuanian Commonwealth to create a third constituent, comparable in status to that of the Grand Duchy of Lithuania.
== Diagnosis == Diagnosis is made by an assessment of history, physical examination in conjunction with blood tests, a liver biopsy, and ultrasound scans imaging and is prompted by prolonged or persistent jaundice, with abnormalities in liver function tests. Ultrasound or other forms of imaging such as radio-isotope liver scans can also be used but final confirmation is usually only reached at the time of exploratory surgery. Ultrasonography will usually show an absent or abnormal gallbladder.
=== Nutritional adjuncts === In the context of managing the adverse effects of chemotherapy, some research has looked at whether omega‑3 supplements might help patients mitigate toxicity and maintain their physical strength. A 2015 review of small studies, alongside more recent 2022 research, found signs that omega‑3s may help patients keep more of their body weight and muscle, support certain aspects of quality of life, and decrease treatment-related toxicity and inflammation. The evidence is still limited and the studies varied, so it is not known how meaningful these effects are. However, reviews note that patients taking omega‑3 supplements alongside conventional therapies do not do worse than those who do not. Similarly, a 2022 meta-analysis and a 2023 systematic review focusing on lung cancer patients undergoing radiotherapy and chemotherapy found that omega-3 supplementation helped improve nutritional status, such as maintaining body weight, and reduced markers of inflammation and treatment toxicity. Additionally, researchers are investigating the molecular mechanisms of omega-3s to see if they might help combat chemoresistance, particularly in breast cancer treatments. Another analysis looking at adults receiving chemotherapy or radiotherapy found that high‑calorie oral nutritional supplements without omega‑3 fats did not help patients maintain their weight, while high‑protein supplements enriched with omega‑3s were linked with better weight maintenance than similar‑calorie products without omega‑3s.
=== In the digestive system === In the digestive system, VIP seems to induce smooth muscle relaxation (lower esophageal sphincter, stomach, gallbladder), stimulate secretion of water into pancreatic juice and bile, and cause inhibition of gastric acid secretion and absorption from the intestinal lumen. Its role in the intestine is to greatly stimulate secretion of water and electrolytes, as well as relaxation of enteric smooth muscle, dilating peripheral blood vessels, stimulating pancreatic bicarbonate secretion, and inhibiting gastrin-stimulated gastric acid secretion. These effects work together to increase motility. It also has the function of stimulating pepsinogen secretion by chief cells. VIP seems to be an important neuropeptide during inflammatory bowel diseases since the communication between mast cells and VIP in colitis, as in Crohn's disease, is upregulated.
== Diagnosis == Epidemiologically, the disorder usually develops slowly and is mainly observed in people over the age of 50. Diagnosis is made on the basis of bone marrow biopsy. Fibrosis grade 2 or 3 defines overt PMF whereas grade 0 or 1 defines prefibrotic primary myelofibrosis. A physical exam of the abdomen may reveal enlargement of the spleen, the liver, or both. Bone marrow biopsy shows fibrosis of the bone marrow. In early stages, this fibrosis is characterised by scattered linear reticulin fibres.
Sources: en.wikipedia.org
== Personal life == On 5 July 2008, Emma Griffiths married Busted member Matt Willis at Rushton Hall, Northamptonshire, after three years of dating. The wedding was featured in OK magazine. She gave birth to their first child, a daughter named Isabelle, on 20 June 2009. On 25 November 2011, the couple had a second child, a son named Ace. On 4 May 2016, Willis gave birth to their third child, a second daughter, named Trixie Grace. In an episode of Who Do You Think You Are?, Willis confirmed that she has longstanding roots in Birmingham, with her family tree being traced back to her great-great-great-grandfather, who was named James Gretton and was listed as a Horn and Hair Merchant in the census records. She also found she had Irish ancestors, a fact that came as a surprise to her. The revelations about her ancestry left her extremely uncomfortable with the actions of one, who she discovered was a violent Orangeman, but overall, she was happy to have found a connection to her more broad Irish heritage. Willis is a supporter of Aston Villa. In August 2019, Willis obtained a qualification as a maternity care assistant following her experience on the W series Delivering Babies. During the COVID-19 pandemic in March 2021, Willis and her husband completed training with St John Ambulance to act as vaccination volunteers. In May 2023, Willis was featured in the documentary, Matt Willis: Fighting Addiction. The documentary, which aired on the BBC on 17 May 2023, followed Willis and her husband as they spoke about the latter's addiction issues.
=== 2006–2013: Rise to prominence and subsequent hiatus === Larter auditioned for the science fiction drama television series Heroes on NBC while living in Los Angeles. She played the characters of Niki Sanders, who suffered from dissociative identity disorder, and Tracy Strauss on the show created by Tim Kring. Larter's initial character Niki Sanders, was a wife, mother, and a former internet stripper from Las Vegas exhibiting superhuman strength and alternate personalities who go by the names of Jessica and Niki. "Ali read for the part and just owned it from the second she walked in," Kring said to the Chicago Tribune, "It was a very impressive audition." In the third and fourth seasons, Larter played the new character of Tracy Strauss, who possessed the ability to freeze objects and later, transform her body into water. Larter took on the title role in Marigold (2007), alongside Salman Khan, an Indian actor. The film was released in August 2007 and revolved around Marigold Lexington, an American actress (Larter) who goes to India and gets caught up in the exotic world of Bollywood. Filming took place in North India and London, commencing in June 2004. In an interview with the BBC, Larter remarked this role was "an opportunity to overcome my fear of singing and dancing because I have no professional training... I really focused on the character and loved this journey she went on and the experiences she had." She was paid a seven-figure salary for her part in the film.
=== Patterns of symptom occurrence === These symptoms often reflect the body's systemic inflammatory response. However, their occurrence and intensity can fluctuate over time, leading to periods of heightened disease activity, referred to as flare-ups, and periods of relative inactivity, known as remissions. The specific presentation of symptoms largely depends on the location and type of autoimmune response. For instance, in rheumatoid arthritis, an autoimmune disease primarily affecting the joints, symptoms typically include joint pain, swelling, and stiffness. On the other hand, type 1 diabetes, which results from an autoimmune attack on the insulin-producing cells of the pancreas, primarily presents with symptoms related to high blood sugar, such as increased thirst, frequent urination, and unexplained weight loss.
==== Integral fast reactor ==== One design of fast neutron reactor, specifically conceived to address the waste disposal and plutonium issues, was the integral fast reactor (IFR, also known as an integral fast breeder reactor, although the original reactor was designed to not breed a net surplus of fissile material). The IFR concept included on-site pyroprocessing to recycle used fuel. The remaining waste would not consist solely of short-lived fission products. Long-lived fission products such as technetium-99 and iodine-129 remain important for disposal, and pyroprocessing also generates waste streams containing salts and fuel cladding. Some fission products could later be separated for industrial or medical uses and the rest sent to a waste repository. The IFR pyroprocessing system uses molten cadmium cathodes and electrorefiners to reprocess metallic fuel directly on-site at the reactor. Such systems co-mingle all the minor actinides with both uranium and plutonium. The systems are compact and self-contained, so that no plutonium-containing material needs to be transported away from the site of the breeder reactor. Breeder reactors incorporating such technology would most likely be designed with breeding ratios very close to 1.00, so that after an initial loading of enriched uranium and/or plutonium fuel, the reactor would then be refueled only with small deliveries of natural uranium. A quantity of natural uranium equivalent to a block about the size of a milk crate delivered once per month would be all the fuel such a 1 gigawatt reactor would need.
== January 5, 1982 (Tuesday) == The U.N. General Assembly voted, 86 to 21 with 34 abstentions, to approve a non-binding resolution calling all members of the United Nations to end aid, trade, and diplomatic ties with Israel to punish it for annexing the Golan Heights. The U.S. used its power, as a permanent member of the UN Security Council, and vetoed the resolution on January 20. South Korea ended a nationwide curfew that had been in place since 1945, and permitted citizens the freedom to be outside from midnight to 4:00 in the morning, a period previously off limits. The curfew remained in effect, however, for areas bordering North Korea. President Chun Doo-hwan said in a statement that South Koreans were "more mature" and that the curfew was no longer necessary. The sinking of the Japanese fishing trawler Akebono Maru No.28 killed 32 members of its crew. The ship was at least 130 miles (210 km) away from Adak Island, one the Aleutian Islands off of the coast of the U.S. state of Alaska when it capsized. Serial killer Charles Jackson Jr. raped and murdered his final victim, Joan Stewart, a biology professor at San Francisco City College near Montclair, California. Jackson, suspected of murdering seven other people in the Bay Area from 1975 to 1981, would be convicted of the murder of Stewart and sentenced to life imprisonment and would die in 2002, before the extent of his killings would be revealed by DNA profiling not available in 1982. Born: Faiza Hasan, Pakistani television actress; in Karachi.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.
No, dihexa is a synthetic compound derived from the structure of angiotensin IV. Angiotensin IV occurs naturally, but dihexa has modifications that change its properties. It is not a standard dietary component.
The main hypothesis is that dihexa interacts with the hepatocyte growth factor system, possibly through c-Met signaling. This interaction may influence synaptogenesis and neuronal plasticity. The exact molecular target remains an active area of study.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.